A single cycle of intravenous immunoglobulin as an adjuvant to rituximab in patients with pemphigus: a retrospective cohort study at a tertiary referral centre
While there have been reports on the combined use of rituximab (RTX) and intravenous immunoglobulin (IVIg) for treating refractory pemphigus, there is a lack of extensive research affirming the value of adding IVIg to the current RTX regimen. In this retrospective cohort study of 76 patients with pemphigus treated with RTX and systemic corticosteroids, RTX + IVIg resulted in similar clinical efficacy, but with a potential reduction in risk of pneumonia. This suggests that IVIg might be a valuable adjuvant for RTX to be considered in certain cases of pemphigus, more to improve safety profile than to ameliorate clinical outcomes.
Authors
- Zijing Yang (ORCID: https://orcid.org/0000-0002-7935-8018)
- Hailun Wang (ORCID: https://orcid.org/0000-0003-3061-9456)
- Shuman Yang (ORCID: https://orcid.org/0000-0002-9169-5850)
- Huiyi Ke (ORCID: https://orcid.org/0000-0001-7445-3473)
- Zhen Fang (ORCID: https://orcid.org/0000-0002-6845-4354)
- Yi Shen (ORCID: https://orcid.org/0000-0002-6548-7089)
- Jingying Wang (ORCID: https://orcid.org/0000-0002-5598-2668)
- Jie Zheng (ORCID: https://orcid.org/0000-0002-7961-6427)
- Haiqin Zhu (ORCID: https://orcid.org/0000-0003-4505-9420)
- Qijun Wang (ORCID: https://orcid.org/0000-0001-6028-5632)
- Wenzhe Zhao (ORCID: https://orcid.org/0000-0003-4745-5611)
- Meng Pan (ORCID: https://orcid.org/0000-0003-4947-9369)
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-11-09
- DOI
- https://doi.org/10.1093/bjd/ljaf449
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00